Your browser doesn't support javascript.
loading
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.
Liu, Chang; Ginn, Helen M; Dejnirattisai, Wanwisa; Supasa, Piyada; Wang, Beibei; Tuekprakhon, Aekkachai; Nutalai, Rungtiwa; Zhou, Daming; Mentzer, Alexander J; Zhao, Yuguang; Duyvesteyn, Helen M E; López-Camacho, César; Slon-Campos, Jose; Walter, Thomas S; Skelly, Donal; Johnson, Sile Ann; Ritter, Thomas G; Mason, Chris; Costa Clemens, Sue Ann; Gomes Naveca, Felipe; Nascimento, Valdinete; Nascimento, Fernanda; Fernandes da Costa, Cristiano; Resende, Paola Cristina; Pauvolid-Correa, Alex; Siqueira, Marilda M; Dold, Christina; Temperton, Nigel; Dong, Tao; Pollard, Andrew J; Knight, Julian C; Crook, Derrick; Lambe, Teresa; Clutterbuck, Elizabeth; Bibi, Sagida; Flaxman, Amy; Bittaye, Mustapha; Belij-Rammerstorfer, Sandra; Gilbert, Sarah C; Malik, Tariq; Carroll, Miles W; Klenerman, Paul; Barnes, Eleanor; Dunachie, Susanna J; Baillie, Vicky; Serafin, Natali; Ditse, Zanele; Da Silva, Kelly; Paterson, Neil G; Williams, Mark A.
Afiliação
  • Liu C; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.
  • Ginn HM; Diamond Light Source Ltd., Harwell Science & Innovation Campus, Didcot, UK.
  • Dejnirattisai W; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Supasa P; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Wang B; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Tuekprakhon A; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Nutalai R; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Zhou D; Division of Structural Biology, The Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Mentzer AJ; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Zhao Y; Division of Structural Biology, The Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Duyvesteyn HME; Division of Structural Biology, The Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • López-Camacho C; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Slon-Campos J; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Walter TS; Division of Structural Biology, The Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Skelly D; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
  • Johnson SA; Peter Medawar Building for Pathogen Research, Oxford, UK.
  • Ritter TG; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Mason C; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Costa Clemens SA; Institute of Global Health, University of Siena, Siena, Brazil; Department of Paediatrics, University of Oxford, Oxford, UK.
  • Gomes Naveca F; Laboratório de Ecologia de Doenças Transmissíveis na Amazônia, Instituto Leônidas e Maria Deane, Fiocruz, Manaus, Amazonas, Brazil.
  • Nascimento V; Laboratório de Ecologia de Doenças Transmissíveis na Amazônia, Instituto Leônidas e Maria Deane, Fiocruz, Manaus, Amazonas, Brazil.
  • Nascimento F; Laboratório de Ecologia de Doenças Transmissíveis na Amazônia, Instituto Leônidas e Maria Deane, Fiocruz, Manaus, Amazonas, Brazil.
  • Fernandes da Costa C; Fundação de Vigilância em Saúde do Amazonas, Manaus, Amazonas, Brazil.
  • Resende PC; Laboratorio de vírus respiratórios-IOC/FIOCRUZ, Rio de Janeiro, Brazil.
  • Pauvolid-Correa A; Laboratorio de vírus respiratórios-IOC/FIOCRUZ, Rio de Janeiro, Brazil; Department of Veterinary Integrative Biosciences, Texas A&M University, College Station, TX, USA.
  • Siqueira MM; Laboratorio de vírus respiratórios-IOC/FIOCRUZ, Rio de Janeiro, Brazil.
  • Dold C; NIHR Oxford Biomedical Research Centre, Oxford, UK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Temperton N; Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent and Greenwich, Chatham Maritime, Kent ME4 4TB, UK.
  • Dong T; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK; Nuffield Department of Medicine, University of Oxford, Oxford, UK; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Ox
  • Pollard AJ; NIHR Oxford Biomedical Research Centre, Oxford, UK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Knight JC; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Crook D; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Lambe T; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Clutterbuck E; NIHR Oxford Biomedical Research Centre, Oxford, UK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Bibi S; NIHR Oxford Biomedical Research Centre, Oxford, UK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Flaxman A; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Bittaye M; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Belij-Rammerstorfer S; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Gilbert SC; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Malik T; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.
  • Carroll MW; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.
  • Klenerman P; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK; Translational Gastroenterology Unit, University of Oxford, Oxford, UK.
  • Barnes E; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK; Translational Gastroenterology Unit, University of Oxford, Oxford, UK.
  • Dunachie SJ; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; Centre For Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand
  • Baillie V; South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology/National Research Foundation, South African Research Ch
  • Serafin N; South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology/National Research Foundation, South African Research Ch
  • Ditse Z; South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology/National Research Foundation, South African Research Ch
  • Da Silva K; South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology/National Research Foundation, South African Research Ch
  • Paterson NG; Diamond Light Source Ltd., Harwell Science & Innovation Campus, Didcot, UK.
  • Williams MA; Diamond Light Source Ltd., Harwell Science & Innovation Campus, Didcot, UK.
Cell ; 184(16): 4220-4236.e13, 2021 08 05.
Article em En | MEDLINE | ID: mdl-34242578
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone progressive change, with variants conferring advantage rapidly becoming dominant lineages, e.g., B.1.617. With apparent increased transmissibility, variant B.1.617.2 has contributed to the current wave of infection ravaging the Indian subcontinent and has been designated a variant of concern in the United Kingdom. Here we study the ability of monoclonal antibodies and convalescent and vaccine sera to neutralize B.1.617.1 and B.1.617.2, complement this with structural analyses of Fab/receptor binding domain (RBD) complexes, and map the antigenic space of current variants. Neutralization of both viruses is reduced compared with ancestral Wuhan-related strains, but there is no evidence of widespread antibody escape as seen with B.1.351. However, B.1.351 and P.1 sera showed markedly more reduction in neutralization of B.1.617.2, suggesting that individuals infected previously by these variants may be more susceptible to reinfection by B.1.617.2. This observation provides important new insights for immunization policy with future variant vaccines in non-immune populations.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / SARS-CoV-2 / Anticorpos Antivirais Limite: Animals / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / SARS-CoV-2 / Anticorpos Antivirais Limite: Animals / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article